Press coverage about Medpace Holdings (NASDAQ:MEDP) has trended somewhat positive on Saturday, Accern Sentiment Analysis reports. Accern identifies negative and positive news coverage by analyzing more than 20 million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Medpace Holdings earned a media sentiment score of 0.10 on Accern’s scale. Accern also assigned news headlines about the company an impact score of 49.3225618650773 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the next few days.

These are some of the headlines that may have impacted Accern Sentiment Analysis’s analysis:

Several brokerages recently weighed in on MEDP. Jefferies Group LLC boosted their price objective on shares of Medpace Holdings from $34.00 to $38.00 and gave the stock a “hold” rating in a research note on Wednesday. Raymond James Financial, Inc. began coverage on shares of Medpace Holdings in a research note on Friday, September 29th. They issued a “market perform” rating on the stock. William Blair cut shares of Medpace Holdings from an “outperform” rating to a “market perform” rating in a research note on Wednesday. They noted that the move was a valuation call. Zacks Investment Research raised shares of Medpace Holdings from a “hold” rating to a “buy” rating and set a $40.00 price objective on the stock in a research note on Friday. Finally, Robert W. Baird boosted their price objective on shares of Medpace Holdings from $32.00 to $35.00 and gave the stock a “neutral” rating in a research note on Tuesday. Seven analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. Medpace Holdings presently has an average rating of “Hold” and a consensus target price of $36.60.

Medpace Holdings (NASDAQ MEDP) traded up $1.22 during mid-day trading on Friday, reaching $37.24. 183,512 shares of the company traded hands, compared to its average volume of 102,308. The firm has a market capitalization of $1,400.45, a price-to-earnings ratio of 25.33, a price-to-earnings-growth ratio of 1.91 and a beta of -0.34. The company has a current ratio of 0.68, a quick ratio of 0.79 and a debt-to-equity ratio of 0.36. Medpace Holdings has a 1-year low of $21.76 and a 1-year high of $39.64.

Medpace Holdings (NASDAQ:MEDP) last released its earnings results on Monday, October 30th. The company reported $0.40 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.36 by $0.04. The business had revenue of $98.68 million for the quarter, compared to analyst estimates of $96.84 million. Medpace Holdings had a net margin of 6.44% and a return on equity of 10.00%. Medpace Holdings’s revenue for the quarter was up 4.1% on a year-over-year basis. During the same quarter in the previous year, the business earned $0.40 earnings per share. equities analysts anticipate that Medpace Holdings will post 1.5 earnings per share for the current year.

In related news, major shareholder Medpace Limited Partnership sold 2,000,000 shares of the business’s stock in a transaction on Tuesday, August 22nd. The shares were sold at an average price of $30.27, for a total value of $60,540,000.00. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. 25.80% of the stock is owned by insiders.

COPYRIGHT VIOLATION WARNING: This report was originally published by Watch List News and is the property of of Watch List News. If you are accessing this report on another website, it was copied illegally and republished in violation of U.S. and international copyright and trademark law. The original version of this report can be accessed at

Medpace Holdings Company Profile

Medpace Holdings, Inc is a clinical contract research organization. The Company provides clinical research-based drug and medical device development services. The Company partners with pharmaceutical, biotechnology, and medical device companies in the development and execution of clinical trials. The Company’s drug development services focus on full service Phase I-IV clinical development services and include development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support.

Insider Buying and Selling by Quarter for Medpace Holdings (NASDAQ:MEDP)

Receive News & Ratings for Medpace Holdings Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medpace Holdings Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.